These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30467074)

  • 21. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.
    Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E
    N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients.
    Schippa S; Iebba V; Santangelo F; Gagliardi A; De Biase RV; Stamato A; Bertasi S; Lucarelli M; Conte MP; Quattrucci S
    PLoS One; 2013; 8(4):e61176. PubMed ID: 23613805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
    Arora K; Naren AP
    Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
    Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
    Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
    Cai ZW; Liu J; Li HY; Sheppard DN
    Acta Pharmacol Sin; 2011 Jun; 32(6):693-701. PubMed ID: 21642944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
    Kerem E; Hirawat S; Armoni S; Yaakov Y; Shoseyov D; Cohen M; Nissim-Rafinia M; Blau H; Rivlin J; Aviram M; Elfring GL; Northcutt VJ; Miller LL; Kerem B; Wilschanski M
    Lancet; 2008 Aug; 372(9640):719-27. PubMed ID: 18722008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cystic Fibrosis Gene Mutation Frequency Among a Group of Suspected Children in King Hussein Medical Center.
    Al-Abadi B; Al-Hiary M; Khasawneh R; Al-Momani A; Bani-Salameh A; Al-Saeidat S; Al-Khlaifat A; Aboalsondos O
    Med Arch; 2019 Apr; 73(2):118-120. PubMed ID: 31391700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
    Kotha K; Clancy JP
    Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials.
    Bell SC; Barry PJ; De Boeck K; Drevinek P; Elborn JS; Plant BJ; Minić P; Van Braeckel E; Verhulst S; Muller K; Kanters D; Bellaire S; de Kock H; Geller DE; Conrath K; Van de Steen O; van der Ent K
    J Cyst Fibros; 2019 Sep; 18(5):700-707. PubMed ID: 31056441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
    Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
    Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study.
    Bagheri-Hanson A; Nedwed S; Rueckes-Nilges C; Naehrlich L
    BMC Pulm Med; 2014 Oct; 14():156. PubMed ID: 25280757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
    Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.
    Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M
    PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.